Larynx Cancer Clinical Trial
Official title:
High Resolution MRI in the Evaluation of Laryngeal Neoplasia
Verified date | October 2017 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine if high resolution MRI can detect early invasion of cartilage by laryngeal carcinoma, and to determine if high resolution MRI may be superior to conventional MRI imaging or CT imaging to detect cartilage invasion.
Status | Terminated |
Enrollment | 3 |
Est. completion date | January 2010 |
Est. primary completion date | January 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with benign or malignant neoplasm of the larynx. - Patients who have undergone prior surgery, radiation therapy, or chemotherapy for cancer of the laryngopharynx will be eligible to participate. - Patients 18 years of age and older at time of evaluation, male and female, all ethnicities. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Pregnancy - Claustrophobia. - Anatomic parameters which preclude scanning, such as limited range of neck motion, or inability to remain flat for at least 15 minutes. - Patients with implanted devices (eg, defibrillator, pacemaker) that are a known contraindication to magnetic resonance imaging. - Allergy to gadolinium contrast. |
Country | Name | City | State |
---|---|---|---|
United States | Stanford University School of Medicine | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tumor stage as determined by HRMRI. | Radiologic tumor stage | 24 to 48 hours | |
Secondary | Estimate the precision of HRMRI in discriminating between edema and tumor in patients with prior radiotherapy or chemotherapy. | Comparison of true tumor dimension as predicted by HRMRI versus true tumor size as shown on final histopathology | 4 to 6 weeks | |
Secondary | Tumor stage as determined by histopathology in excised larynges. | Pathological tumor stage | 4 to 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Completed |
NCT03292341 -
Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients.
|
N/A | |
Completed |
NCT03653039 -
Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy
|
N/A | |
Completed |
NCT05746780 -
Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
|
||
Recruiting |
NCT05793151 -
Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy
|
N/A | |
Completed |
NCT01700647 -
Breath Testing in Early and Late Larynx Cancer
|
N/A | |
Completed |
NCT00600223 -
Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches
|
N/A | |
Completed |
NCT00169247 -
Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation
|
Phase 2 | |
Recruiting |
NCT03759431 -
Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02586207 -
Pembrolizumab in Combination With CRT for LA-SCCHN
|
Phase 1 | |
Recruiting |
NCT04057209 -
VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer
|
N/A | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT06086119 -
Quality of Life and Voice Perception in Patients Laryngoctomized Phonatory Wearers
|
||
Suspended |
NCT04368702 -
CONFIRM: Magnetic Resonance Guided Radiation Therapy
|
N/A | |
Completed |
NCT05217147 -
An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma
|
||
Active, not recruiting |
NCT03082534 -
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00158652 -
Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC
|
Phase 3 | |
Terminated |
NCT03479463 -
Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy
|
||
Completed |
NCT03096808 -
Adaptive Radiotherapy for Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT03028766 -
WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer
|
Phase 1 |